Hyperlipoproteinemia Type I: Clinical Trials

7 trials for Hyperlipoproteinemia Type I, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 unknown, 1 withdrawn. 7 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 5, Unknown 1, Withdrawn 1
Phase 32Completed 1, Unknown 1
Phase 11Completed 1

Follow Hyperlipoproteinemia Type I: new trials by email Literature Review of Hyperlipoproteinemia Type I trials Research Report on Hyperlipoproteinemia Type I

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)
AKCEA-ANGPTL3-LRx - Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency
Phase 2CompletedAkcea Therapeutics32017-12-212021-01-07
Alipogene Tiparvovec for the Treatment of LPLD Patients
alipogene tiparvovec, Prednisolone, Cyclosporins - LPL Deficiency
Phase 2WithdrawnUniQure Biopharma B.V.2016-10-012017-08-17
Orlistat for the Treatment of Type I Hyperlipoproteinemia
Orlistat - Hyperlipoproteinemia Type I, Hypertriglyceridemia
Phase 2CompletedUniversity of Texas Southwestern Medical Center22015-12-012023-02-08
Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia
CAT-2003, Placebo - Lipoprotein Lipase Deficiency, Familial, Hyperlipoproteinemia Type I
Phase 2CompletedCatabasis Pharmaceuticals132014-03-012016-07-21
Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia
LCQ908, Placebo - Hyperlipoproteinemia
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals82010-05-012020-12-17
Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects
Alipogene Tiparvovec (AMT-011), Human LPL [S447X], mycophenolate mofetil, cyclosporine - Familial Lipoprotein Lipase Deficiency
Phase 2 / Phase 3CompletedAmsterdam Molecular Therapeutics52009-02-012011-09-29
Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]
Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Mycophenolate mofetil, cyclosporine - Familial Lipoprotein Lipase Deficiency
Phase 2 / Phase 3UnknownAmsterdam Molecular Therapeutics142007-08-012011-09-30

Narrower conditions

Hypertriglyceridemia (3)  ·  Hyperlipoproteinemias (2)  ·  Dyslipidemias (1)  ·  Familial hyperchylomicronemia syndrome (1)  ·  Genetic Diseases, Inborn (1)  ·  Hyperlipidemias (1)  ·  Lipid Metabolism Disorders (1)  ·  Lipid Metabolism, Inborn Errors (1)  ·  Metabolic Diseases (1)  ·  Metabolism, Inborn Errors (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7)  ·  Nutritional and Metabolic Diseases (7)  ·  Dyslipidemias (6)  ·  Genetic Diseases, Inborn (6)  ·  Hyperlipidemias (6)  ·  Lipid Metabolism Disorders (6)  ·  Lipid Metabolism, Inborn Errors (6)  ·  Metabolic Diseases (6)  ·  Metabolism, Inborn Errors (6)  ·  Hyperlipoproteinemias (5)

Interventions

Alipogene tiparvovec (3)  ·  Mycophenolic Acid (3)  ·  Cyclosporine (2)  ·  Cyclosporins (1)  ·  IONIS-ANGPTL3-LRx (1)  ·  Methylprednisolone (1)  ·  Methylprednisolone Hemisuccinate (1)  ·  Orlistat (1)  ·  Prednisolone (1)  ·  pradigastat (1)  ·  vupanorsen (1)

Sponsors

Amsterdam Molecular Therapeutics (2)  ·  Akcea Therapeutics (1)  ·  Catabasis Pharmaceuticals (1)  ·  Novartis Pharmaceuticals (1)  ·  UniQure Biopharma B.V. (1)  ·  University of Texas Southwestern Medical Center (1)

Countries

Canada (6)  ·  United States (2)

Top investigators

Abhimanyu Garg, MD (1)  ·  Daniel Gaudet, MD, Ph.D. (1)

Results publications

PMID 22438229, PMID 22717743, PMID 25889044, PMID 29659879